secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sanara MedTech Inc. (SMTI)
CIK:        0000714256
Form:       8-K
Filed at:   2026-01-23T23:59:59+00:00
Accession:  0001493152-26-003316
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sanara MedTech reports preliminary FY 2025 revenue ~$103M, guides FY 2026 revenue $116M-$121M
--------------------------------------------------------------------------------

- Q4 2025 net revenue expected $27.2M-$27.7M, up 3-5% YoY; excluding $1.8M BIASURGE sales in Q4'24, growth 11-13%.
- FY 2025 net revenue expected $102.7M-$103.2M, ~19% YoY growth; excluding $1.8M BIASURGE, growth 21-22%.
- FY 2026 guidance: net revenue $116M-$121M, growth 13-17% from 2025 midpoint.
- Cash $16.6M, long-term debt $46.0M at Dec 31, 2025 (vs $15.9M cash, $30.7M debt a year earlier).
- BIASURGE receives Vizient Innovative Technology contract; OsStic launch planned Q1 2027 pending FDA clearance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/714256/000149315226003316/0001493152-26-003316-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/714256/000149315226003316/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-003316

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer